A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05579691 |
Recruitment Status :
Completed
First Posted : October 14, 2022
Last Update Posted : February 16, 2024
|
Sponsor:
Larimar Therapeutics, Inc.
Information provided by (Responsible Party):
Larimar Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | December 4, 2023 |
Actual Study Completion Date : | December 4, 2023 |
Publications: